oasis 1 oral semaglutide 50 mg nejm 2023 obesity 🚨 25 delivers double-digit weight loss in OASIS-4 (Phase 3 trial) - Novel strategies for medical management

Avery Brown of NYU Langone Health noted: as many as 70% of patients may discontinue treatment within one year. Patients who stayed on continuous GLP-1 therapy for a full year lost meaningfully more weight than those who didnt still less than surgery patients, but the researchers were explicit that adherence changes the picture substantially

Many of my clients still need to plan meals, track intake, work with a dietitian, build habits, and stay active to reach their goals

side effects: no undesirable effects are known for this product

And headaches are common during the adjustment period

Weight Loss Results You Can See and Feel